Drug Search Results
More Filters [+]

Imetelstat

Alternative Names: imetelstat, GRN163L, GRN-163L
Latest Update: 2024-10-15
Latest Update Note: News Article

Product Description

Imetelstat is a first-in-class telomerase inhibitor that could change the course of blood cancers—changing lives for the better. The development of imetelstat is grounded on Nobel Prize-winning scientific discoveries by early Geron collaborators that expanded the understanding of telomeres and telomerase and their role in the proliferation of cancer cells. Using this knowledge, Geron scientists pioneered a new approach in which oligonucleotides (short single strands of synthetic DNA or RNA) inhibit the activity of telomerase, an enzyme that helps maintain telomeres and enables the continued proliferation of malignant cells. (Sourced from: https://www.geron.com/research-and-development/imetelstat/)

Mechanisms of Action: telomerase Inhibitor

Novel Mechanism: No

Modality: Nucleic Acid

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Geron
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Imetelstat

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Colombia, Czech Republic, Denmark, France, Georgia, Germany, Hungary, India, Israel, Italy, Korea, Malaysia, Netherlands, Poland, Portugal, Russia, Singapore, Spain, Taiwan, Turkey, United Kingdom, United States

Active Clinical Trial Count: 9

Highest Development Phases

Phase 3: Myelodysplastic Syndrome|Myelofibrosis

Phase 2: Acute Myeloid Leukemia|Preleukemia

Phase 1: Acute Monocytic Leukemia|Acute Myelomonocytic Leukemia|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia,

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MYF3001

P3

Recruiting

Myelofibrosis

2026-11-25

63935937MDS3001

P3

Unknown Status

Myelodysplastic Syndrome

2026-10-13

PEPN2312

P1

Recruiting

Acute Myelomonocytic Leukemia|Preleukemia|Chronic Myeloid Leukemia|Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Acute Myeloid Leukemia|Acute Monocytic Leukemia|Juvenile Myelomonocytic Leukemia,

2026-06-30

IMpress_001

P2

Unknown Status

Acute Myeloid Leukemia|Myelodysplastic Syndrome

2026-06-30

Recent News Events